Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profound Medical ( (TSE:PRN) ) has issued an update.
On March 13, 2026, Profound Medical announced that its multicenter CAPTAIN randomized controlled trial comparing the MRI-guided TULSA Procedure to robotic radical prostatectomy in men with organ-confined, intermediate-risk prostate cancer met its primary safety endpoint. The study, which exceeded its enrollment target with 211 patients treated across North America and Europe by August 2025, demonstrated that TULSA achieved statistically superior preservation of both erectile function and urinary continence at six months, with 50% of patients maintaining both versus 24% after surgery.
Data presented at the EAU 2026 Congress showed TULSA also delivered better quality-of-life outcomes, including higher pad-free continence rates, comparable or better erectile function, zero blood loss, no routine overnight hospital stay, faster return to work, and significantly fewer serious complications than robotic radical prostatectomy. While secondary oncologic outcomes for the TULSA arm are still pending 12‑month biopsy and MRI readouts, the trial is designed to show non-inferior cancer control with superior functional outcomes, positioning TULSA as a potentially paradigm-shifting alternative that could advance toward inclusion in prostate cancer treatment guidelines if longer-term efficacy data confirm these early safety and quality-of-life advantages.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$7.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform supports MRI-guided prostate therapy across the spectrum of prostate disease, while its Sonalleve system offers non-surgical, MRI-guided treatment for bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions such as uterine fibroids and adenomyosis.
The company focuses on enabling precise, real-time, image-guided interventions that aim to improve clinical outcomes and quality of life versus traditional surgery or radiation. By targeting whole-gland and focal treatments with minimal blood loss, no incisions, and shorter hospital stays, Profound is positioning its technologies as less invasive alternatives that may help redefine standards of care in interventional oncology and women’s health.
Average Trading Volume: 19,644
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$275.5M
Learn more about PRN stock on TipRanks’ Stock Analysis page.
